Merrimack Pharmaceuticals, Inc.
MACK
MACK was delisted on the 17th of May, 2024.
62 hedge funds and large institutions have $98.5M invested in Merrimack Pharmaceuticals, Inc. in 2023 Q2 according to their latest regulatory filings, with 18 funds opening new positions, 18 increasing their positions, 10 reducing their positions, and 6 closing their positions.
486% more call options, than puts
Call options by funds: $2.38M | Put options by funds: $407K
200% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 6
80% more repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 10
24% more funds holding
Funds holding: 50 → 62 (+12)
8% more capital invested
Capital invested by funds: $91M → $98.5M (+$7.5M)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$5.68M |
| 2 |
State Street
Boston,
Massachusetts
|
+$1.54M |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$1.42M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.23M |
| 5 |
Northern Trust
Chicago,
Illinois
|
+$1.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Invesco
Atlanta,
Georgia
|
-$2.59M |
| 2 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
-$1M |
| 3 |
BFM
Boothbay Fund Management
New York
|
-$888K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$818K |
| 5 |
Jane Street
New York
|
-$459K |
MACK Hedge Fund Activity: Q2 2023 in Review
62 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Merrimack Pharmaceuticals, Inc. (MACK) for Q2 2023, worth a combined $98.5M — up 8.2% from $91M a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new MACK positions and 6 closed out — a net gain of 12 holders — while 18 added to existing stakes and 10 trimmed.
The largest buyer was BlackRock, adding an estimated $5.68M. The largest seller was Invesco, exiting entirely with an estimated $2.59M sold.
- 62 institutional investors held Merrimack Pharmaceuticals, Inc. (MACK) as of Q2 2023, up from 50 in Q1 2023.
- Funds reported $98.5M of Merrimack Pharmaceuticals, Inc. stock for Q2 2023, up 8.2% quarter-over-quarter.
- 18 funds opened new Merrimack Pharmaceuticals, Inc. positions in Q2 2023 and 6 closed out, a net change of +12 holders.
- The largest Merrimack Pharmaceuticals, Inc. buyer in Q2 2023 was BlackRock, an estimated $5.68M added.
- The largest Merrimack Pharmaceuticals, Inc. seller in Q2 2023 was Invesco, an estimated $2.59M sold.
Based on aggregated 13F filings for Q2 2023.